“Playing detective” in a case of paraneoplastic polymyositis

Adult-onset polymyositis (PM) belongs to the idiopathic inflammatory myopathy (IIM) group and manifests with proximal muscle weakness, elevated muscle enzymes and positive myositis- specific antibodies. The subset of autoantibodies can indicate a higher risk for cancer association. An 82-year-old di...

Full description

Saved in:
Bibliographic Details
Published inRevista română de reumatologie Vol. 31; no. 4; pp. 180 - 183
Main Authors Juganaru, Elena, Cobilinschi, Claudia, Constantinescu, Cosmin, Hoara, Petre, Iosif, Cristina, Mehic, Florentina, Balanescu, Andra
Format Journal Article
LanguageEnglish
Published Amaltea Medical Publishing House 31.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Adult-onset polymyositis (PM) belongs to the idiopathic inflammatory myopathy (IIM) group and manifests with proximal muscle weakness, elevated muscle enzymes and positive myositis- specific antibodies. The subset of autoantibodies can indicate a higher risk for cancer association. An 82-year-old diabetic patient, with multiple cardio-vascular comorbidities, was hospitalized for muscle weakness of the upper girdle, dysphagia and dysphonia, accompanied by elevated serum muscle enzymes. Muscle biopsy showed an inflammatory infiltrate while immunological assays found positive ANA and anti-NXP2 antibodies. The diagnosis of PM was established, thus a screening for underlying neoplasia was required. Upper endoscopy visualized an area of ectopic mucosa in the esophagogastric junction and the biopsy confirmed a squamous cell carcinoma in situ. Patient had favorable muscle outcome under methylprednisolone pulse therapy. It is worth noting that polymyositis is more rarely associated with cancers as compared to dermatomyositis (DM). In conclusion, the type of antibodies identified in myositis can represent an alarm signal for oncologic screening, making possible an early diagnosis and efficient treatment of a hidden tumor.
ISSN:1843-0791
2069-6086
DOI:10.37897/RJR.2022.4.4